MYC RNAi-Pt Combination Nanotherapy for Metastatic Prostate Cancer Treatment
Technical Report,30 Sep 2015,29 Sep 2019
The Johns Hopkins University School of Medicine Baltimore United States
Pagination or Media Count:
The main objective of this project is to develop an innovative nanotherapy modality by combining platinum Pt chemotherapy and MYC targeting RNA interference RNAi for more effective treatment of metastatic prostate cancer PCa. Over the entire period of this project, we made significant accomplishments in each of the proposed tasks. We successfully developed, characterized, and optimized a reduction responsive nanoparticle NP platform for effective delivery of siRNA and cisplatin prodrug. The siMYC NPs and siMYC-Pt NPs were extensively tested in vitro using different PCa cell lines including Pt-resistant cells, and the combination nanotherapy showed potent antitumor efficacy in subcutaneously xenografted PCa mouse model without obvious in vivo toxicities.
- Medicine and Medical Research